High-Risk Resectable NSCLC
1 clinical trials · Condition
◉ Watch High-Risk Resectable NSCLC
| Record | Firm | Date |
|---|---|---|
| ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer (NCT03732664) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-10-01 |
Track High-Risk Resectable NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.